SYRE
Spyre Therapeutics Inc.
92.70$
-0.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +260.9% | -19.9% | -37.2% | +50.9% | -29.6% | -3.9% | +5.9% | +2.0% | +2.6% | +30.5% | +5.5% | – | |
| – | – | – | -939.5% | – | +4.3% | -105.3% | – | – | -138.1% | – | -3,759.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -63.9% | +197.6% | +14.8% | – | -499.0% | -100.0% | – | -68.4% | -1,089.7% | – | -626.5% | – | |
| – | – | – | – | – | – | – | -100.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +5.2% | -99.8% | +3,450.0% | +1,665.3% | -99.9% | +484.8% | -735.2% | – | -96.1% | +3,430.0% | – | |
| – | – | -60.3% | -571.9% | – | -31.7% | -329.4% | – | -150.5% | – | -44.9% | +465.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.